InflaRx (IFRX) EBITDA Margin (2018 - 2026)
InflaRx (IFRX) posted EBITDA Margin of 450.39% for Q1 2026, up 513.19% sequentially from 73.45% in Q4 2025, and up 3653868.0% YoY from N/an in Q1 2025.
InflaRx (IFRX) EBITDA Margin (2018 - 2026) Analysis & Trends
InflaRx has reported EBITDA Margin for 9 years, with the latest figure at 450.39% in Q1 2026.
- Quarterly EBITDA Margin rose 3653868.0% year-over-year to 450.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.01% (up 1463.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
- EBITDA Margin advanced to 450.39% in Q1 2026 per IFRX's latest filing, from 73.45% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1785.36% in Q1 2022 and troughed at 242200.14% in Q2 2024.
- A 5-year average of 23291.42% and a median of 7.31% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin sank 24279327 bps in 2024, then jumped 20943998 bps in 2025.
- Over 5 years, EBITDA Margin stood at 2314.11% in 2022, then soared by 99 bps to 29.67% in 2023, then jumped by 376 bps to 81.84% in 2024, then declined by 10 bps to 73.45% in 2025, then surged by 513 bps to 450.39% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 450.39%, 73.45%, and 39769.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.75% |
| 10 | InflaRx | 140.63 Mn | -43.63 Mn | 2.74 Bn | -17,899.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 450.39% |
| Dec 31, 2025 | 73.45% |
| Sep 30, 2025 | -39,769.22% |
| Jun 30, 2025 | -32,760.16% |
| Mar 31, 2025 | -36,088.30% |
| Dec 31, 2024 | 81.84% |
| Sep 30, 2024 | -12,405.24% |
| Jun 30, 2024 | -242,200.14% |
| Mar 31, 2024 | -34,655.19% |
| Dec 31, 2023 | -29.67% |
| Sep 30, 2023 | -0.02% |
| Jun 30, 2023 | 593.13% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | -2,314.11% |
| Sep 30, 2022 | 1,290.98% |
| Jun 30, 2022 | -7.31% |
| Mar 31, 2022 | 1,785.36% |
| Dec 31, 2021 | 0.20% |
| Sep 30, 2021 | 1,905.72% |
| Jun 30, 2021 | -100.00% |